Cargando…

P2Y1 agonist HIC in combination with androgen receptor inhibitor abiraterone acetate impairs cell growth of prostate cancer

P2Y receptors belong to the large superfamily of G-protein-coupled receptors and play a crucial role in cell death and survival. P2Y1 receptor has been identified as a marker for prostate cancer (PCa). A previously unveiled selective P2Y1 receptor agonist, the indoline-derived HIC (1-(1-((2-hydroxy-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Le, Hien Thi Thu, Murugesan, Akshaya, Candeias, Nuno R., Ramesh, Thiyagarajan, Yli-Harja, Olli, Kandhavelu, Meenakshisundaram
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940814/ https://www.ncbi.nlm.nih.gov/pubmed/35129730 http://dx.doi.org/10.1007/s10495-022-01716-1

Ejemplares similares

Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity
por: Doan, Phuong, et al.
Publicado: (2021)

Synthesis and preclinical validation of novel P2Y1 receptor ligands as a potent anti-prostate cancer agent
por: Le, Hien Thi Thu, et al.
Publicado: (2019)

Synthesis and Preclinical Validation of Novel Indole Derivatives as a GPR17 Agonist for Glioblastoma Treatment
por: Nguyen, Phung, et al.
Publicado: (2021)

Anticancer activity of THMPP: Downregulation of PI3K/ S6K1 in breast cancer cell line
por: Palanivel, Suresh, et al.
Publicado: (2020)

Identifying the miRNA Signature Association with Aging-Related Senescence in Glioblastoma
por: Gnanavel, Mutharasu, et al.
Publicado: (2021)

Programmed cell death detection methods: a systematic review and a categorical comparison
por: Kari, Sana, et al.
Publicado: (2022)

Glioblastoma Multiforme Stem Cell Cycle Arrest by Alkylaminophenol through the Modulation of EGFR and CSC Signaling Pathways
por: Doan, Phuong, et al.
Publicado: (2020)

Battling Glioblastoma: A Novel Tyrosine Kinase Inhibitor with Multi-Dimensional Anti-Tumor Effect (Running Title: Cancer Cells Death Signalling Activation)
por: Viswanathan, Anisha, et al.
Publicado: (2019)

Erratum: Viswanathan, A., et al. Battling Glioblastoma: A Novel Tyrosine Kinase Inhibitor with Multi-Dimensional Anti-Tumor Effect (Running Title: Cancer Cells Death Signalling Activation). Cells 2019, 8, 1624
por: Viswanathan, Anisha, et al.
Publicado: (2020)

Alkylaminophenol Induces G1/S Phase Cell Cycle Arrest in Glioblastoma Cells Through p53 and Cyclin-Dependent Kinase Signaling Pathway
por: Doan, Phuong, et al.
Publicado: (2019)

Methanodibenzo[b,f][1,5]dioxocins as Novel Glutaminase Inhibitor with Anti-Glioblastoma Potential
por: Murugesan, Akshaya, et al.
Publicado: (2023)

Cell segmentation by multi-resolution analysis and maximum likelihood estimation (MAMLE)
por: Chowdhury, Sharif, et al.
Publicado: (2013)

Origins of Transcriptional Transition: Balance between Upstream and Downstream Regulatory Gene Sequences
por: Sala, Adrien, et al.
Publicado: (2015)

Targeting Orphan G Protein-Coupled Receptor 17 with T0 Ligand Impairs Glioblastoma Growth
por: Doan, Phuong, et al.
Publicado: (2021)

Benzenesulfonamide Analogs: Synthesis, Anti-GBM Activity and Pharmacoprofiling
por: Murugesan, Akshaya, et al.
Publicado: (2023)

In vivo kinetics of transcription initiation of the lar promoter in Escherichia coli. Evidence for a sequential mechanism with two rate-limiting steps
por: Kandhavelu, Meenakshisundaram, et al.
Publicado: (2011)

Dynamics of transcription driven by the tetA promoter, one event at a time, in live Escherichia coli cells
por: Muthukrishnan, Anantha-Barathi, et al.
Publicado: (2012)

Cell-to-cell diversity in protein levels of a gene driven by a tetracycline inducible promoter
por: Smolander, Olli-Pekka, et al.
Publicado: (2011)

Androgen dynamics and serum PSA in patients treated with abiraterone acetate
por: Ryan, C J, et al.
Publicado: (2014)

Abiraterone acetate, an inhibitor of adrenal androgen synthesis in “hormone refractory prostate cancer”
por: Goel, Arun Kumar, et al.
Publicado: (2011)

Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer
por: Harshman, Lauren C., et al.
Publicado: (2013)

Abiraterone Acetate
Publicado: (2012)

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
por: Rehman, Yasser, et al.
Publicado: (2012)

In vivo single-molecule kinetics of activation and subsequent activity of the arabinose promoter
por: Mäkelä, Jarno, et al.
Publicado: (2013)

Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of Neuroblastoma via Targeting Androgen Receptor
por: Hu, Zengchun, et al.
Publicado: (2021)

In vitro characterization of arylhydrazones of active methylene derivatives
por: Palanivel, Suresh, et al.
Publicado: (2018)

Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
por: Linden-Castro, Edgar, et al.
Publicado: (2014)

Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy
por: Kim, Ki Bom, et al.
Publicado: (2015)

Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade
por: Nagai, Takashi, et al.
Publicado: (2018)

Abiraterone Acetate Withdrawal Syndrome: Does It Exist?
por: Gauthier, Hélène, et al.
Publicado: (2012)

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023)

Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone
por: Kanao, Kent, et al.
Publicado: (2022)

A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high‐risk prostate cancer
por: Tani, Masaru, et al.
Publicado: (2023)

Neoadjuvant androgen deprivation therapy combined with abiraterone acetate in patients with locally advanced or metastatic prostate cancer: When to perform radical prostatectomy?
por: Xu, Ziyang, et al.
Publicado: (2022)

Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor–Expressing Salivary Gland Cancer: A Phase II Trial
por: Locati, Laura D., et al.
Publicado: (2021)

First Line Androgen Deprivation Therapy Duration Is Associated with the Efficacy of Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer after Docetaxel
por: Li, Jian-Ri, et al.
Publicado: (2017)

Cancer research in the era of next-generation sequencing and big data calls for intelligent modeling
por: Yli-Hietanen, Jari, et al.
Publicado: (2015)

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
por: Werutsky, Gustavo, et al.
Publicado: (2019)

Redirecting abiraterone metabolism to fine tune prostate cancer anti-androgen therapy
por: Li, Zhenfei, et al.
Publicado: (2016)

Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_imfq0jve3v8aq8q7kf7gkv7vtq